Blood Res.  2019 Dec;54(4):285-288. 10.5045/br.2019.54.4.285.

Beta-2 microglobulin as a prognostic factor of primary central nervous system lymphoma

• Hyung J
• Hong JY
• Kim S
• Ryu JS
• Huh J
• Suh C

• KMID: 2466596
• DOI: http://doi.org/10.5045/br.2019.54.4.285

Abstract

No abstract available.

MeSH Terms

Central Nervous System*
Lymphoma*

Figure

• 

  Fig. 1 Overall survival from the initiation of first-line treatment.

Reference

1. Haldorsen IS, Espeland A, Larsson EM. Central nervous system lymphoma: characteristic findings on traditional and advanced imaging. AJNR Am J Neuroradiol. 2011; 32:984–992.

2. van der Sanden GA, Schouten LJ, van Dijck JA, et al. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer. 2002; 94:1548–1556.

3. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011; 105:1414–1418.

4. O'Neill BP, Decker PA, Tieu C, Cerhan JR. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am J Hematol. 2013; 88:997–1000.

5. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003; 21:266–272.

6. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006; 24:5711–5715.

7. Munshi NC, Anderson KC, Bergsagel PL, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011; 117:4696–4700.

8. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27:4555–4562.

9. Hagberg H, Killander A, Simonsson B. Serum beta 2-microglobulin in malignant lymphoma. Cancer. 1983; 51:2220–2225.

10. Shi C, Zhu Y, Su Y, Chung LW, Cheng T. Beta2-microglobulin: emerging as a promising cancer therapeutic target. Drug Discov Today. 2009; 14:25–30.